

BEST AVAILABLE COPY

Leucocyte Typing V

White Cell Differentiation Antigens

**Proceedings of the Fifth
International Workshop
and Conference
Held in Boston, USA
3-7 November, 1993**

Volume One

Edited by

**Stuart F. Schlossman, Laurence Boumsell, Wally Gilks,
John M. Harlan, Tadamitsu Kishimoto, Chikao Morimoto,
Jerome Ritz, Stephen Shaw, Roy Silverstein, Timothy Springer,
Thomas F. Tedder and Robert F. Todd**

**Oxford New York Tokyo
OXFORD UNIVERSITY PRESS
1995**

EXHIBIT B

BEST AVAILABLE COPY

Oxford University Press, Walton Street, Oxford O. 1DP

**Oxford New York
Athens Auckland Bangkok Bombay
Calcutta Cape Town Dar es Salaam Delhi
Florence Hong Kong Istanbul Karachi
Kuala Lumpur Madras Madrid Melbourne
Mexico City Nairobi Paris Singapore
Taipei Tokyo Toronto
and associated companies in
Berlin Ibadan**

Oxford is a trade mark of Oxford University Press

**Published in the United States
by Oxford University Press Inc., New York**

**© The Organizing Committee of the Fifth International Conference on
Human Leucocyte Differentiation Antigens and Oxford University Press, 1995**

**All rights reserved. No part of this publication may be
reproduced, stored in a retrieval system, or transmitted, in any
form or by any means, without the prior permission in writing of Oxford
University Press. Within the UK, exceptions are allowed in respect of any
fair dealing for the purpose of research or private study, or criticism or
review, as permitted under the Copyright, Designs and Patents Act, 1988, or
in the case of reprographic reproduction in accordance with the terms of
licences issued by the Copyright Licensing Agency. Enquiries concerning
reproduction outside those terms and in other countries should be sent to
the Rights Department, Oxford University Press, at the address above.**

**This book is sold subject to the condition that it shall not,
by way of trade or otherwise, be lent, re-sold, hired out, or otherwise
circulated without the publisher's prior consent in any form of binding
or cover other than that in which it is published and without a similar
condition including this condition being imposed
on the subsequent purchaser.**

A catalogue record for this book is available from the British Library

**Library of Congress Cataloging in Publication Data
(Data available)**

**ISBN 0 19 2626384 Volume 1
ISBN 0 19 2623761 Two volume set
(Available only as a two volume set)**

**Typeset by Dobbie Typesetting Limited, Tavistock, Devon
Printed in Great Britain by
Butler and Tanner Ltd, Frome, Somerset**

identical pattern of tyrosine phosphorylated polypeptides was observed. Prominent phosphorylated polypeptides were identified with *M*_r of 110, 72, and 40 kDa. Incubation of K-562 cells with MA73 (2ZC115) failed to induce a similar pattern of phosphorylated polypeptides. Incubation with the cross-linking antibody alone, GAM F(ab')₂, similarly did not induce novel phosphorylated polypeptides.

The pattern of tyrosine phosphorylation observed following cross-linking of anti-CD32 mAb is consistent with data previously reported utilizing Fab fragments of mAb IV.3 that showed that the 40-kDa tyrosine phosphorylated protein was FcγRII [8]. The identities of the other tyrosine phosphorylated substrates of *M*_r 110 and 72 kDa are currently under investigation.

The observation that mAb MA23 (BAS62-11) induced a similar pattern of tyrosine phosphorylated polypeptides but yet does not recognize CD32 suggests that this mAb binds an antigen on the surface of K-562 cells via the Fab domain and then activates FcγRII via its Fc region. This could be accomplished by: (1) formation of cellular immune complexes that could bind to FcγRII on other K-562 cells; or (2) tripartite engagement of IgG molecules on the same cell with subsequent cross-linking by the secondary antibody. This finding indicates that ascites containing whole immunoglobulins of an mAb directed against a different cell surface molecule could induce FcγRII-mediated tyrosine phosphorylation. Thus it points out the necessity of using Fab or F(ab')₂ fragments of mAb when investigating the cellular signal

transduction mechanisms of any receptors on cells expressing FcγR. The physical cross-linking of such intact immunoglobulin molecules may produce patterns of tyrosine phosphorylated proteins similar to those induced by cross-linking of FcγRII alone.

Acknowledgement

These studies were supported by NIH grant CA38055.

References

1. Ravetch, J. V. and Kinet, J.-P. *Ann. Rev. Immunol.* 9, 457 (1991).
2. Brooks, D. G., Qui, W. Q., Luster, A. L., and Ravetch, J. V. *J. exp. Med.* 170, 1369 (1989).
3. Huang, M., Indik, Z., Brass, L. F., Hoxie J. A., Schreiber, A. D., and Brugge, J. S. *J. Biol. Chem.* 267, 5467 (1992).
4. Scholl, P. R., Ahern, D., and Geha, R. S. *J. Immunol.* 149, 1751 (1992).
5. Liao, F., Shin, H. S., and Rhee, S. G. *Proc. natl Acad. Sci., USA* 89, 3659 (1992).
6. Salcedo, T. W. and Flett, H. B. *Cell Prolif.* 24, 383 (1991).
7. Looney, R. J., Abraham, G. N., and Anderson, C. L. *J. Immunol.* 136, 1641 (1986).
8. Ghazizadeh, S. and Flett, H. B. *J. Immunol.* 152, 30 (1994).
9. Flett, H. B. *Clin. Immunol. Immunopathol.* 59, 222 (1991).

M8.2 Specificity of CD32 mAb for FcγRIIa, FcγRIIb1, and FcγRIIb2 expressed in transfected mouse B cells and BHK-21 cells

PETRA BUDDE, VOLKER WEINRICH, PETER SONDERMANN, NILS BEWARDER, ANDREAS KILIAN, OLAF SCHULZECK, and JÜRGEN FREY

Six monoclonal antibodies (mAb) of the CD32 panel were analysed for their specificity against the various FcγRII isoforms expressed in the FcγR - mouse B-cell line IIA1.6 [1] and BHK-21 cells [2]. In addition, we compared the reactivity of the mAb with the respective receptors homologously expressed in the human B-cell line Daudi (FcγRIIb1 + and FcγRIIb2 +) as well as K-562 cells (FcγRIIaHR + /LR +; HR = high

responder and LR = low responder). Besides the six Workshop antibodies, we included three new mAb obtained in our laboratory, 1A4, IIA5, and IIBD2, which were compared with an mAb MA179 (AT10) known to recognize all CD32 isoforms [3].

Using FACS analysis, we found that the two mAb MA23 (BAS62-11) and MA73 (2ZC115) did not react with any of the FcγRII, independent of the cell lines

Δ NOTICE: THIS MATERIAL MAY BE PROTECTED BY COPYRIGHT LAW (TITLE 17 U.S. CODE)

ATTORNEY DOCKET NUMBER: 11183-003-999
SERIAL NUMBER: 10524.134
REFERENCE: C09

BEST AVAILABLE COPY

Table 1 Reactivity of mAb with homologously and heterologously expressed CD32 isotypes

CD32 isotypes ¹	Reactivity of mAb ²									
	MA179 (AT10)	MR7 (IV.3)	MA23 (BAS62-11)	MA72 (KB61)	MA73 (ZZC115)	MA128 (FLJ8.26)	MA126 (C10M5)	IA4	IIIA5	IIID2
HLA-6 cell lines										
FcγRIIIaLR	++	++	0	++	0	+	++	0	0	0
FcγRIIIaHR	++	++	0	++	0	+	+	0	0	0
FcγRIIb1	++	0	0	++	0	+	0	0	0	0
FcγRIIb2	++	0	0	++	0	+	0	0	0	0
BHK-21 cell lines										
FcγRIIIaLR	++	++	0	++	0	++	++	0	++	+
FcγRIIIaHR	++	++	0	++	0	++	++	0	++	ND
FcγRIIb1	++	++	0	++	0	++	++	0	++	++
FcγRIIb2	++	++	0	++	0	++	++	0	++	++
Other cell lines										
Daudi	++	(±)	0	++	0	++	+	++	0	0
K-562	++	+++	0	++	0	++	++	0	0	0

¹The FcγRII isotypes were transfected into FcγR - mouse B-cell line HLA-6 and BHK-21 cells as described [1]. mAb were incubated with stable clones expressing the respective isotypes under saturating conditions.

²Bound mAb were detected using fluorescein isothiocyanate (FITC)-labelled F(ab')₂ fragment of goat anti-mouse IgG + IgM. Background fluorescence was detected using the respective mouse isotype controls (IgG/IgM) and the FcR-parental cell lines. 0, No reactivity; ±, very weak reactivity; + to +++ indicates increasing levels of reactivity; ND, not done.




Fig. 1 Reactivity of CD32 mAb on CD19+ human B cells prepared from tonsils. After T-cell rosetting 98 per cent of the cells were CD19+. Cells (8×10^5) were incubated with the various Workshop mAb (1:100 diluted) and mAb AT10 and 1A4 (Fc γ RIIb-specific) as culture supernatants, followed by incubation with a fluorescein isothiocyanate (FITC)-labelled goat anti-mouse IgG+IgM F(ab')₂ fragment and analysed by flow cytometry.

studied (Table 1). mAb MA128 (FL18.26) recognizes Fc γ RIIa, Fc γ RIIb1, and Fc γ RIIb2 equally well, independently of the cell line studied. In contrast, mAb MA72 (KB61) shows a preferential binding to Fc γ RIIb1 and Fc γ RIIb2 in IIA1.6 cells (Table 1). mAb MR7 (IV.3) and MA126 (CIKM5) showed a strong preferential binding to Fc γ RIIa compared to Fc γ RIIb1 and Fc γ RIIb2, when expressed either in mouse or human B cells. Interestingly, this could only be observed in mouse B cells (IIA1.6) but not in BHK-21 cells. In this cell line the Fc γ RIIb isoforms are also recognized by MR7 (IV.3) and MA126 (CIKM5). Therefore, either different glycosylation patterns of the respective Fc γ RIIb isoforms or associated surface molecules in B cells are responsible for the varying antibody specificity. None of the mAb reacted with CD16-Fc γ RIIa chimeric receptors containing either 23 or 47 amino acids (aa) of the extracellular region of Fc γ RIIa (plus transmembrane and cytoplasmic region) [2]. Among the Workshop antibodies tested on human tonsillar B cells, only mAb MA72 (KB61) and MA128 (FL18.26) gave positive results (Fig. 1). In contrast to all transfected cell lines analysed as well as Daudi and K-562 cells, MA23 (BAS62-11) gave bright fluorescence signals on human tonsillar B cells (Fig. 1).

Using a synthetic peptide (aa 30-39 of the mature protein) of Fc γ RIIb2 as well as Fc γ RIIb2 expressed in *Escherichia coli* we raised a panel of mAb with varying specificity. mAb 1A4 (IgM) directed against the synthetic peptide shows a strong specificity for Fc γ RIIb expressed in human B cells and B-cell lines comparable to that of mAb MA179 (AT10) and MA72 (KB61) (Fig. 1; Table 1). Interestingly, this mAb does not react with Fc γ RIIb1 and Fc γ RIIb2 expressed in mouse B cells (IIA1.6) as well as in BHK-21 cells (Table 1). Further studies (not described) revealed, that mAb 1A4 mostly reacts with activated B cells. The specificity of the antibody was verified by immunoprecipitation of Fc γ RIIb1 and Fc γ RIIb2 from Daudi cells (Table 2). The mAb II1A5 and II8D2 were raised against the Fc γ RIIb2 expressed in *E. coli* and were selected on BHK-21 cells expressing Fc γ RIIb2. In FACS analyses mAb II1A5 and II8D2 recognize Fc γ RIIa and Fc γ RIIb isoforms only when they are expressed on BHK-21 cells. In contrast, in Western blot analyses both antibodies detected Fc γ RII, independently of the cell line expressing the receptors (Table 2). Here, mAb II8D2 shows specificity for the Fc γ RIIb isoforms, whereas mAb II1A5 recognizes both Fc γ RIIa and Fc γ RIIb. Thus, it is possible to differentiate between Fc γ RIIa and Fc γ RIIb isoforms expressed in different cells and cell lines by Western blot analysis.




Fig. 2 Immunoprecipitation of homologously and heterologously expressed CD32 using mAb FL18.26. Immunoprecipitation and detection were performed as described in the legend to Table 2. The figure shows a representative result of the precipitation experiments summarized in Table 2.

The efficiency of the Workshop antibodies for immunoprecipitation of Fc γ RII isoforms from different cells was analysed using transfected BHK-21 and IIA1.6 cells as well as Daudi cells. The Fc γ RII precipitation was judged by immunoblotting using the new mAb IIIA5. Among the antibodies tested, only mAb AT10 and FL18.26 were able to bind both Fc γ RIIa and Fc γ RIIb isoforms with affinities sufficient to isolate the immune complexes (Table 2). These results confirm the data obtained by FACS analysis (Table 1). Using mAb MR7 (IV.3) we could only isolate the Fc γ RIIa from BHK-21 and IIA1.6 cells. The reactivity of MR7 (IV.3) against the Fc γ RIIb isoforms expressed in BHK-21 cells observed by FACS analysis (Table 1) must be a fairly weak binding because we could not isolate these Fc γ RII by immunoprecipitation (Table 2). Comparable results were obtained with mAb CIKMS5. The only difference is that CIKMS5 is more efficient in immunoprecipitating the Fc γ RIIaLR alloform (Table 2). The counterpart to MR7 (IV.3) and MA126 (CIKMS5) for immunoprecipitation is mAb MA72 (KB61), which specifically reacts with the Fc γ RIIb isoforms (Table 2). This differential reactivity is not

Table 2 Immunoprecipitation efficiency of anti-CD32 mAb with homologously and heterologously expressed receptor isoforms*

mAb		Immunoprecipitation efficiency with [†]						
Workshop code	Clone name	BHK-21		IIA1.6		BHK-21	IIA1.6	Daudi
		FcγRIIaHR	FcγRIIaLR	FcγRIIaHR	FcγRIIaLR	FcγRIIb2	FcγRIIb2	FcγRIIb
MR7	IV.3	+++	+++	+++	+++	-	-	-
MA23	BAS62-11	-	-	-	-	-	-	-
MA72	KB61	±	±	±	±	+++	+++	+
MA73	22C115	-	-	-	-	+++	+++	+
MA128	FL18.26	++	++	++	++	++	++	+
MA126	CIKMS	++	+++	+	+++	-	-	-
MA179	AT10	+++	+++	+++	+++	++	++	+
	IIIA5	++	++	-	-	++	-	-
	IIID2	++	-	-	-	++	-	-
	IA4	ND	ND	ND	ND	ND	ND	ND

Cells (see footnote to Table 1) were incubated with the mAb under saturating conditions at 4 °C (except for mAb MA73 where the cells were lysed before adding the antibody). The cells were subsequently lysed in modified RIPA buffer (10 mM Tris-HCl, pH 7.2; 1% w/v Triton-X-100; 1% sodium deoxycholate; 0.1% sodium dodecyl sulfate (SDS); 150 mM NaCl; 5 mM Na-EDTA; 4 mM phenylmethylsulfonyl fluoride (PMSF); 1 TIU/ml aprotinin). The cell-free supernatant was subjected to Protein A + G-Sepharose (30 min, 4 °C). Bound immune complexes were eluted using sample buffer and were subjected to SDS-polyacrylamide gel electrophoresis (PAGE). After blotting on to nitrocellulose membranes, the various Fc γ RII isoforms were detected using mAb IIID2 (Fc γ RIIb) and IIIA5 (Fc γ RIIa + Fc γ RIIb). Bound mAb was detected after incubation with peroxidase-labelled goat anti-mouse IgG + IgM using the ECL chemiluminescence detection system (Amersham).

†ND, Not done. -, No reaction; ±, very weak reactivity; + to +++ indicates increasing levels of reactivity.